GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Other Gross PPE

NRIX (Nurix Therapeutics) Other Gross PPE : $68.20 Mil (As of Aug. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics Other Gross PPE?

Nurix Therapeutics's Other Gross PPE for the quarter that ended in Aug. 2024 was $68.20 Mil.

Nurix Therapeutics's quarterly Other Gross PPE increased from Feb. 2024 ($67.53 Mil) to May. 2024 ($69.20 Mil) but then declined from May. 2024 ($69.20 Mil) to Aug. 2024 ($68.20 Mil).

Nurix Therapeutics's annual Other Gross PPE increased from Nov. 2021 ($35.41 Mil) to Nov. 2022 ($42.56 Mil) and increased from Nov. 2022 ($42.56 Mil) to Nov. 2023 ($66.62 Mil).

Nurix Therapeutics Other Gross PPE Historical Data

The historical data trend for Nurix Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics Other Gross PPE Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Other Gross PPE
Get a 7-Day Free Trial 13.30 16.78 35.41 42.56 66.62

Nurix Therapeutics Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.19 66.62 67.53 69.20 68.20

Nurix Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Nurix Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Other Gross PPE
Comparable Companies
AVIR VNDA OVID MGTX IGMS RPHM QURE PGEN FUSN KALV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Website
http://www.nurixtx.com
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
Christine Ring officer: General Counsel C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Houte Hans Van officer: Chief Financial Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen officer: Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff officer: EVP and COO C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman director C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang officer: Chief Business Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129